Evidence map›Paper›PMID 41940810›Full record

ArticleAntimicrobial agents and chemotherapy2026

Case Commentary: When one target is not enough-PBP3 insertions and target redundancy in

Madison E Stellfox, Yohei Doi

Abstract readComment
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Madison E StellfoxDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-1478-5190
Yohei DoiDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-9620-2525

Funding

Genetic and phenotypic adaptations of vancomycin-resistant Enterococcus faecium during recurrent bloodstream infectionK08AI185312 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Madison Elaine Stellfox · 2024 to 2026
$513k
Defining high-risk genomic groups of Stenotrophomonas maltophiliaR21AI185663 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DOI, YOHEI · 2025 to 2025
$481k
NIAID NIH HHS K08 AI185312NIAID NIH HHS R21 AI185663NIH HHS K08AI185312NIH HHS R21AI185663
6 · The paper itself

Abstract

This challenging clinical case highlights the impact of PBP3 insertions in

Indexed as

Anti-Bacterial AgentsEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsPenicillin-Binding ProteinsAzabicyclo CompoundsAztreonambeta-Lactamasesbeta-Lactam Resistancebeta-LactamsCase Reports as TopicHumansImipenemMicrobial Sensitivity TestsAnti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-Lactamasesbeta-LactamsEscherichia coli ProteinsImipenemPenicillin-Binding Proteinsrelebactambeta-lactam resistancePBP insertionstarget redundancy

Identifiers

PMID41940810
PMCPMC13148057

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.